vimarsana.com

Latest Breaking News On - Odium glucose co transporter 2 inhibitors - Page 3 : vimarsana.com

Semaglutide Prescribing Surged in the Past Year

Will Kidney Disease Patients Finally Receive New Drug Class?

Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?

Higher Fracture Risk Not Seen With SGLT2 Inhibitors

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.